

#513
1/12/01


MAILING CERTIFICATE

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington D.C. 20231 on

Jan. 10, 2001 by Kay Bulen Kay Bulen
Date Signature (print name)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Doherty et al.
Filing Date: 31 July 2000
Serial No.: 09/630,155
For: HER-2 BINDING ANTAGONISTS
Art Unit: 1642
Examiner: J. Hunt
Docket: 49321-10
Date: 10 January 2001



RECEIVED

JAN 19 2001

TECH CENTER 1600/2900

Box Non-fee Amendment
Assistant Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir or Madam:

Please amend the specification (Sequence Listing at pages 25-29) by substituting the enclosed corrected Sequence Listing pages 25-29. The amendments are in response to the NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES, attached to the Office Communication, dated 12 December 2000. No new matter has been added. Entry of the Amendment is respectfully requested.

REMARKS

Applicant's, while including a sequence listing in the above-identified divisional application (*i.e.*, at pages 25-29), failed to submit a separate sequence listing. Accordingly, applicants now submit the appropriate sequence listing in paper (C.F.R. 1.821(c)) and computer-readable form (C.F.R. 1.821(e)), along with applicant's statement under (C.F.R. 1.821(f)). Minor corrections to the Sequence Listing, as originally disclosed in the specification, have been made to bring the sequence listing into conformity with the requirements of C.F.R. 1.821-1.825. The presently-submitted Sequence Listing conforms with that of the underlying parent application (Serial No. 09/234,208). No new matter has been added.